Having started the day with the price at exactly 1.00 my OCD is liking the correlational of buys & sells against the percentage movement. 3.1% means a trade of 103.1 etc etc. Now if we could just start tomorrow at 2.00 that would be lovely.
All goes back to the quality of the images. Quite simply Bleepa images are of diagnostic quality enabling important decisions to be made remotely, the others don't. What's the point in having an app that only does half the job. Competition is healthy but quality will win out here.
Saw it going back up and was tempted to sell what I bought here and go back but that's proper chasing and from experience that'll usually end in failure. Almost impossible to buy at the lowest and sell at the highest and I made a nice profit so ain't all bad I guess.
Unless yours was the 8.40 trade I don't think you've been spiked even though it may feel like it at the mo. Having ridden avct up from the low 40s I sold a huge chunk this morning at just below 90 convinced it was going lower. Put it in here, doh. That's up and this is down. Hey ho.
I'd think with news on Flu-V 20p would be conservative. I've been since the Hvivo days. When the phase II results came out it went from high teens to a high of around 1.40 and that was with out it being monetised.
I've topped up this morning. Surprised (well, not really with this holding) that with the news over the weekend the SP is still down here. There's a serious disconnection between the value of what's on offer and the market cap here. Even without the lottery ticket we're well overdue a rerate IMO
Well done Ian, you know it makes sense. Now, while the rest of us are hoping for a nice juicy Monday RNS I'm guessing you're not quite so keen. They were cheap Friday close of play so should be all good for you if nothing changes between now and 8am Monday.
It claims.... "Bleepa system was rolled out by the NHS" Wouldn't it be nice if it was nationwide! The latest tweeks to Bleepa that allow data collection on patient pathways could be quite a powerful research tool apart from the longer functionality beyond Covid-19
Australasian Institute of Digital Health (AIDH) We are delighted to welcome onboard Feedback Medical @FBKmed as partners for #FromTheFrontlines virtual conference. Their revolutionary product @BleepaMe was listed as one of the top 10 digital health solutions for a national COVID-19 response in the UK.
I'm out. Had a good run and very nearly bagged. Placing shares tomorrow worry me on rise like this, the temptation for them to get their stake back and have a free ride might drive the price down tomorrow so I'll watch with interest and no doubt kick myself when I'm proved wrong! If it comes back I'll buy as long term the future looks brighter here than it has for a while.
A few bits of publicity out there, largely reflecting the wording of the RNS. We really need this to be picked up by the mainstream media. Interest is gathering, it's only a matter of time before this explodes again.